Preclinical Evaluation of no-Carrier-Added [131I]Meta-Iodobenzyl Guanidine, for the Treatment of Tumours Transfected with the Noradrenaline Transporter Gene

Publisher： Bentham Science Publishers

E-ISSN： 1875-628x|1|1|50-57

ISSN： 1570-1808

Source： Letters in Drug Design & Discovery, Vol.1, Iss.1, 2004-01, pp. : 50-57

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Experimental Targeted Therapy Using [211At]meta-Astatobenzylguanidine and Transfection of the Noradrenaline Transporter Gene

By  

Current Radiopharmaceuticals, Vol. 1, Iss. 3, 2008-09 ,pp. : 197-202

Bentham Science Publishers

Access to resources Recommend Favorite

Direct Nucleophilic 18F-Fluorination of Electron Rich Arenes: Present Limits of No-Carrier-Added Reactions

By  

Current Radiopharmaceuticals, Vol. 3, Iss. 3, 2010-07 ,pp. : 163-173

Bentham Science Publishers

Access to resources Recommend Favorite

No-Carrier-Added [18F]Fluorobenzene Derivatives as Intermediates for Built-up Radiosyntheses

By  

Current Radiopharmaceuticals, Vol. 3, Iss. 2, 2010-04 ,pp. : 127-160

Bentham Science Publishers

Access to resources Recommend Favorite

Necrosis affinity evaluation of 131 I-hypericin in a rat model of induced necrosis

By Kong Ming  

Journal of Drug Targeting, Vol. 21, Iss. 6, 2013-07 ,pp. : 604-610

Informa Healthcare

Access to resources Recommend Favorite

Actions of amphetamine derivatives and cathinone at the noradrenaline transporter

By Cleary L.   Docherty J.R.  

European Journal of Pharmacology, Vol. 476, Iss. 1, 2003-08 ,pp. : 31-34

Elsevier

Access to resources Recommend Favorite